We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Gyros Platform Chosen by Merck Millipore in Expansion of Contract Service Offerings

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Gyros Platform Chosen by Merck Millipore in Expansion of Contract Service Offerings"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Gyros AB, a leader in the automation of miniaturized immunoassays, announced today that Merck Millipore’s BioPharma Services organization, the world’s leading large molecule lab, has purchased  a Gyrolab™ xP workstation to expand the Company’s contract research services for the biopharmaceutical industry.

Merck Millipore is among the first contract service organizations in the United States to invest in a Gyrolab workstation. The unique microfluidic technology will allow Merck Millipore to miniaturize assays for all of the organization’s contract service programs, which include immunogenicity, pharmacokinetics (PK), and current Good Manufacturing Practice (cGMP) testing, as well as for fit-for-purpose biomarker assays.

“As a contract service organization to pharma, our reputation is founded on quality, reliability and cost-effectiveness," said Christina Shasserre, Head of Discovery and Development Solutions for Merck Millipore. “To this end, we are continually looking for solutions that enhance our throughput and output to exceed our customers' expectations. The Gyrolab workstation is an integral part of this equation.”

"In our evaluation of the Gyrolab xP workstation, we were particularly impressed with the system’s high level of accuracy; rapid method development and validation; and delivery of robust assays—even  in 50% matrix," said Ron Bowsher, Chief Scientist for BioPharma Services at Merck Millipore. “Incorporating Gyrolab technology into our offering will give us a competitive advantage for servicing the fields of pharmacokinetics, anti-drug antibody, and host-cell protein (HCP) testing.”

Commenting on the announcement, Erik Walldén, CEO at Gyros, said: “We see Merck Millipore’s investment as strong confirmation that our offering delivers what is important to our customers. From a company perspective, this signals a growing acceptance of our technology, and a major step in our expansion, within the US market.”